Fractyl Health (NASDAQ:GUTS) vs. Zealand Pharma A/S (OTCMKTS:ZLDPF) Critical Comparison

Fractyl Health (NASDAQ:GUTS) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

Earnings and Valuation

This table compares Fractyl Health and Zealand Pharma A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90,000.00	593.75	-$140.95 million	($0.88)	-4.58
Zealand Pharma A/S	$1.40 billion	1.79	$977.29 million	$6.03	5.78

Zealand Pharma A/S has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Fractyl Health has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Fractyl Health and Zealand Pharma A/S, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1	1	3	0	2.40
Zealand Pharma A/S	0	9	1	1	2.27

Fractyl Health presently has a consensus price target of $66.00, suggesting a potential upside of 1,537.72%. Given Fractyl Health’s stronger consensus rating and higher probable upside, equities analysts clearly believe Fractyl Health is more favorable than Zealand Pharma A/S.

Profitability

This table compares Fractyl Health and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Zealand Pharma A/S	58.86%	17.56%	16.17%

Summary

Zealand Pharma A/S beats Fractyl Health on 8 of the 13 factors compared between the two stocks.

About Fractyl Health

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.